In another study, it was demonstrated that the upregulated serum L-FABP levels are related to a degree of fibrosis and inflammation in the liver, which indicates that serum L-FABP can be a noninvasive biomarker used to assess the severity of fibrosis and inflammation in nonalcoholic steatohepatitis patients [72]. Here, FABP1 is linked to metabolic dysfunction-associated steatohepatitis.